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Repetitive Transcranial Magnetic Stimulation
with Resting-State Network Targeting
for Treatment-Resistant Depression in Traumatic Brain Injury:
A Randomized, Controlled, Double-Blinded Pilot Study
Shan H. Siddiqi,1–3 Nicholas T. Trapp,6 Carl D. Hacker,4 Timothy O. Laumann,3 Sridhar Kandala,3 Xin Hong,5
Ludwig Trillo,3 Pashtun Shahim,2 Eric C. Leuthardt,4 Alexandre R. Carter,5 and David L. Brody2,5
Abstract
Repetitive transcranial magnetic stimulation (rTMS) has demonstrated antidepressant efficacy but has limited evidence in
depression associated with traumatic brain injury (TBI). Here, we investigate the use of rTMS targeted with individualized
resting-state network mapping (RSNM) of dorsal attention network (DAN) and default mode network (DMN) in subjects
with treatment-resistant depression associated with concussive or moderate TBI. The planned sample size was 50 with first
interim analysis planned at 20, but only 15 were enrolled before the study was terminated for logistical reasons. Subjects
were randomized to 20 sessions of bilateral rTMS (4000 left-sided excitatory pulses, 1000 right-sided inhibitory pulses) or
sham. Treatment was targeted to the dorsolateral prefrontal cluster with maximal difference between DAN and DMN
correlations based on resting-state functional magnetic resonance imaging with individualized RSNM. Mean improvement
in the primary outcome, Montgomery-Asberg Depression Rating Scale (MADRS), was 56% – 14% (n = 9) with active
treatment and 27% – 25% (n = 5) with sham (Cohen’s d = 1.43). One subject randomized to sham withdrew before starting
treatment. There were no seizures or other significant adverse events. MADRS improvement was inversely correlated with
functional connectivity between the right-sided stimulation site and the subgenual anterior cingulate cortex (sgACC; r =
-0.68, 95% confidence interval 0.03-0.925). Active treatment led to increased sgACC-DMN connectivity (d = 1.55) and
increased sgACC anti-correlation with the left- and right-sided stimulation sites (d = -1.26 and -0.69, respectively). This
pilot study provides evidence that RSNM-targeted rTMS is feasible in TBI patients with depression. Given the dearth of
existing evidence-based treatments for depression in this patient population, these preliminarily encouraging results
indicate that larger controlled trials are warranted.
Keywords: depression; fMRI; rTMS; TBI
Introduction
Repetitive transcranial magnetic stimulation (rTMS) isa noninvasive technique for selective excitation or inhibition
of focal brain regions.1 Excitatory rTMS over the left dorsolateral
prefrontal cortex (DLPFC) has consistently demonstrated antide-
pressant efficacy, leading to its U.S. Food and Drug Administration
(FDA) approval for medication-resistant major depressive disorder
in 2008.2–5 Positive results have been reported with a wide variety
of stimulation protocols, although the optimal treatment approach
remains a topic of open debate.6 Similarly positive results have
been reported for depression associated with various neurological
disorders such as stroke and Parkinson’s disease.7,8 Despite this
established efficacy, rTMS has not been investigated in the setting
of depression associated with traumatic brain injury (TBI),9 which
affects nearly half of TBI patients.10
While traditional approaches to antidepressant pharmacotherapy
and psychotherapy have failed to demonstrate benefit in random-
ized controlled trials for TBI-associated depression,11,12 rTMS may
hold unique promise due to its structural neurorehabilitative effects.
Excitatory stimulation also has been shown to accelerate stroke
recovery when applied over the affected cortex.13 Contralateral
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inhibitory rTMS has demonstrated comparable efficacy both in
stroke recovery14 and in major depression.6,15,16 The combination
of excitatory treatment and contralateral inhibitory treatment can
further improve efficacy in both neurorehabilitative17 and antide-
pressant settings.6 This is consistent with emerging evidence that
rTMS modulates interhemispheric connectivity, which also is af-
fected by TBI.18 Further, animal models have successfully used
rTMS to restore cortical excitability,19 which is often compromised
following TBI.20
A prevailing concern limiting the study of rTMS in the setting of
TBI is that these patients may be at higher risk of seizures, which is
a rare side effect of rTMS9 and a common complication of severe
TBI.21 However, a growing body of literature has established the
fact that this risk is not elevated in patients with diffuse/multi-focal
axonal injury (which constitutes the majority of patients with TBI),
and the elevated risk is unique to patients with a history of pene-
trating injury or intracranial hemorrhage.21,22 While the risk of
headaches also has limited the use of rTMS for this indication, prior
work suggests that the treatment may actually improve post-
concussive headaches.23
Anatomical targeting of neuromodulation introduces additional
challenges due to TBI-induced disruptions in functional connec-
tivity (FC),24–26 which may affect functional network topography in
these patients. rTMS is traditionally targeted to scalp regions
overlying DLPFC, which shows substantial inter-individual topo-
graphic variability even in healthy individuals.27,28 This may ex-
plain the heterogeneity in rTMS response between patients and
between studies.29 Functional imaging literature suggests that the
treatment exerts its antidepressant effects via modulation of con-
nectivity between DLPFC, default mode network (DMN), and sub-
genual anterior cingulate cortex (sgACC),30–32 regions which have
been heavily implicated in major depression.30,33–35 Recent efforts to
optimize rTMS targeting have focused on identifying DLPFC targets
that are maximally anti-correlated with sgACC.29,31,36 This may
approximate the mechanisms of sgACC deep brain stimulation,
which has shown promising efficacy for treatment-resistant major
depression.35
The antidepressant effects of sgACC deep brain stimulation
appear to be associated with changes in externally-oriented
attention-shifting and self-referential interoceptive awareness; this
interaction has been proposed to represent a ‘‘depression switch’’
involving sgACC.37 These cognitive processes have been linked to
the dorsal attention network (DAN) and DMN, respectively.38–40
DMN generally shows strong functional connectivity with sgACC
and anti-correlation with DAN.39,41 DAN usually includes a node
in DLPFC which was unrecognized until recently, possibly because
its location shows substantial inter-individual variability.28,42,43
Interactions between these systems are likely affected after TBI,
which has been associated with disrupted FC in anterior cingulate
cortex, DLPFC, DAN, and DMN.24,25,44,45
Existing approaches for targeting rTMS have focused on con-
nectivity with seed regions defined by standardized anatomical
atlases.29,31 Such methods can predict efficacy of different rTMS
targets at a group level, but have not been able to identify indi-
vidualized treatment targets. A substantial emerging body of work
has focused on developing and validating individual-level brain
parcellation methods using resting-state functional magnetic reso-
nance imaging (rsfMRI).46–48 These approaches can be used to
generate individualized maps of DAN and DMN in an effort to
identify rTMS targets for optimally modulating sgACC. Given the
known disruptions in DAN and DMN that are inherent to TBI,24,25
individualized rTMS targeting may represent a promising approach
for resolving the heterogeneity in this patient population. Thus, we
hypothesized that rTMS targeted using an individualized rsfMRI
approach expected to modulate sgACC would be feasible and im-
prove mood in patients with treatment-resistant depression asso-
ciated with TBI. We reasoned that if successful, this would set the
stage for future direct comparisons between different rTMS tar-
geting approaches.
Methods
Standard protocol approvals, registrations,
and participant consents
The study protocol was approved by the Human Research Pro-
tection Office at Washington University School of Medicine in St.
Louis, Missouri. All individuals gave informed written consent.
The study was registered with ClinicalTrials.gov (NCT02980484).
All procedures, outcome measures, and analyses were pre-specified
and registered with the Open Science Foundation (osf.io/vjddq).49
The study was reviewed on a weekly basis by the investigators for
safety.
Subjects
Referrals were solicited from the TBI clinics at Washington
University in St. Louis and the Rehabilitation Institute of St. Louis.
Participants included adults (age 18–65) with a primary diagnosis
of TBI and a minimum score of 10 on the Montgomery-Asberg
Depression Rating Scale (MADRS). All subjects met Diagnostic
and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
criteria for a major depressive episode secondary to TBI (ICD-10
F06.32—Mood disorder due to known physiological condition with
major depressive-like episode) that persisted after at least one trial
of antidepressant pharmacotherapy. Subjects with elevated seizure
risk, including those with penetrating or hemorrhagic TBI, were
excluded. TBI severity was classified according to the patient’s ex-
isting clinical diagnosis, which was based on the consensus guide-
lines defined in 1993 by the American Congress of Rehabilitation
Medicine.50 Other baseline clinical criteria were determined based
on review of medical records. Intracranial metallic implants or
neurostimulation devices were considered contraindications to
treatment. Additional excluded diagnoses included dementia,
moderate–severe autism spectrum disorder, bipolar I disorder,
schizophrenia spectrum disorders, active psychosis, or dysphoria
clearly explained by etiology other than TBI or major depressive
disorder (MDD; such as a substance-induced mood disorder). No
changes or recommendations were made for the subject’s usual
medical treatment regimen as part of the study.
Measures
The primary outcome measure was the MADRS.51 DSM-5 di-
agnostic assessment and MADRS were conducted by one of two
senior psychiatry residents (SHS, NTT) who were blinded to the
subjects’ group assignments. For each subject, all MADRS as-
sessments were administered by the same physician. MADRS was
completed at baseline, after the 10th treatment, and after the final
treatment.
Additional measures collected at baseline and after the full
treatment course included personality testing with the temperament
and character inventory (TCI)52; self-report mood scales in the
National Institutes of Health (NIH) Toolbox Emotion Battery53;
cognitive testing with the NIH Toolbox Cognitive Battery (CB)54;
self-report headache Likert scores and six-question Headache Im-
pact Test (HIT-6)55; and an expert psychiatric evaluation based on
DSM-5 diagnostic criteria. Structural and functional MRI scans
were performed at baseline and at the end of the treatment course
for all subjects. At the end of the treatment course, all subjects were
1362 SIDDIQI ET AL.
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asked to guess their group assignments to assess the adequacy of
blinding.
Sample size
A recent meta-analysis of studies investigating rTMS for MDD
demonstrated a weighted mean effect size of 0.86 for improvement
in depressive symptom scores.56 However, this meta-analysis did
not include the effects of structural MRI-guided neuronavigation,
which has been shown to improve efficacy of rTMS with a relative
effect size of 0.56.57 This suggests that the efficacy of neuronavi-
gated rTMS in comparison with sham may be estimated as the sum
of these two values, or 1.42. Further, bilateral rTMS is likely more
effective than unilateral rTMS6. We thus conservatively antici-
pated an effect size of between 0.86 and 1.42.
These values were used to estimate the sample size required to
achieve an 80% chance of detecting an effect at p < 0.05 using an
unpaired two-tailed t-test. This yielded a required sample size be-
tween 20 and 46 subjects. We thus planned to conduct an interim
analysis for sample size re-estimation after enrolling 20 subjects
with total maximum enrollment of 50 subjects.
MRI acquisition and analysis
Acquisition. Pre- and post-treatment images were acquired
with a 3T Siemens Magnetom Prisma magnetic resonance scanner
(Siemens, Erlangen, Germany). Functional acquisition included
16.5 min of resting-state blood oxygen level–dependent (BOLD)
scans in three runs (416 frames per run, 48 axial slices using multi-
band acquisition factor of 4, 3 mm cubic voxel resolution, repetition
time [TR] 800 msec, echo time [TE] 26.6 msec, flip angle 61, im-
aging matrix 72 · 72). Structural acquisition included one T1 Mag-
netization Prepared Rapid Acquisition Gradient Echo (MPRAGE)
structural sequence (176 frames, 0.9375 · 0.9375 · 1 mm voxel res-
olution, TR 2400 msec, TE 3.19 msec, flip angle 8, imaging matrix
256 · 256). This T1 weighted scan required approximately 5 min.
The complete imaging protocol required approximately 30 min per
subject.
Processing. Spatial alignment, atlas registration, motion
scrubbing at framewise displacement of 0.2 mm and frequency
filter for respiratory artifact,58 nuisance regression, global signal
regression, temporal filtering, spatial smoothing, and motion epoch
interpolation were performed using in-house scripts by the methods
described by Power and colleagues.59 Resulting time courses were
used for all subsequent resting-state functional connectivity ana-
lyses.
Individualized resting-state network mapping. Processed
time courses were used to construct individual-level resting-state
functional connectivity maps via the multi-layer perceptron-based
machine learning classifier as described in Hacker and col-
leagues.47 This method involves a machine learning algorithm that
has been trained to recognize resting-state networks (RSNs) based
on each voxel’s seed-based connectivity profile. The algorithm
classifies individual voxels in a patient’s brain based on likelihood
of membership in one of seven networks (dorsal attention, ventral
attention, frontoparietal control, default mode, motor, language,
and visual).
These seven RSNs were chosen meta-analytically based on task
fMRI studies of 10 distinct networks, each containing several foci
of activity. After refining these foci to maximize intra-network
correlation and minimize inter-network correlation, three of the
original networks (cingulo-opercular network, affective network,
and distinct foveal and peripheral vision networks) were not clearly
discriminable at the individual level.47 However, the optimal
number of networks in the brain remains a topic of active debate
due to improved granularity with newer RSN mapping procedures,
which are outside the scope of the present work. The Yeo 2011
seven-network parcellation is still widely used as a consensus defi-
nition of network boundaries since it agrees with boundaries defined
by task activation studies.41 This approach was chosen because it has
been used successfully for preoperative neurosurgical mapping,60
while newer approaches to individualized RSN mapping have
not been implemented clinically to our knowledge. Some recent
techniques carry the advantage of further subclassifying certain
RSNs,27,46 but we were unable to identify a theoretical basis for
targeting a specific subdivision of DAN and DMN in this study.
rTMS target selection. Individualized rTMS treatment tar-
gets were identified as described in Siddiqi and colleagues, 2018
(preprint at biorxiv.org/content/early/2017/11/21/151696). The in-
dividualized RSN maps were used to calculate the absolute differ-
ence between likelihoods of DAN and DMN membership for each
voxel. The image was masked to include only voxels within 6 mm of
the outer surface of a standard Talairach atlas template brain in order
to include only superficial gray matter regions,61 which are more
readily accessible via rTMS.62 As an approximation of DLPFC, a
second mask was applied to include only voxels within 20 mm of
Brodmann areas 9 and 46, which was a smaller radius than described
in previous retrospective work.29 A smaller size was chosen to avoid
inclusion of excessively anterolateral regions (which are likely to
produce substantial facial muscle contraction) and excessively
posterior regions (which are associated with increased seizure risk
due to possible inadvertent stimulation of motor cortex). Positive
clusters in the resulting image were identified using FSL’s cluster
algorithm (FMRIB Software Library, Oxford, UK)63,64 with an
image threshold of 75% of the maximum Z-score. The centers of
gravity of the peak clusters in each hemisphere were chosen as
optimal left- and right-sided rTMS stimulation sites (exemplars
shown in Fig. 1). These coordinates were transformed from Ta-
lairach to native space using the 4dfp tool suite. In four subjects who
volunteered to receive two additional resting-state fMRI scans for
reliability assessment, test–retest variability of the target coordina-
tes ranged between 0.9 and 8.3 mm (Fig. 1B).
Study treatment
Subjects were randomized to receive active rTMS or sham
treatment with a Magstim Rapid-2 stimulator. Active treatment was
delivered using a double 70-mm air-cooled coil. Sham treatment
was delivered using a double 70-mm Alpha sham coil, which
produces a similar sound, but delivers only a weak magnetic pulse
that is not adequate for substantial stimulation of deep or superficial
nerves. All other study procedures, including neuronavigation,
were identical for the two groups.
Treatment course included 20 daily sessions of bilateral rTMS
using high-frequency left-sided stimulation (4000 pulses at 10 Hz
frequency with 5-sec trains and 20-sec inter-train interval) followed
by low-frequency right-sided stimulation (a single train of 1000
pulses with 1 Hz frequency). A dorsolateral prefrontal node, which
was identified based on individual-level functional connectivity
mapping as described above, was targeted using the Brainsight
neuronavigation system (Rogue Research, Montreal, Canada). The
intensity of rTMS stimulation was 120% of resting motor threshold
(RMT). RMT was determined bilaterally by measuring electro-
myogram (EMG) activation in the contralateral abductor pollicis
brevis muscle. An EMG activation of at least 50 lV was considered
to be a positive test. The overall RMT was determined using the
titration algorithm implemented by the TMS motor threshold as-
sessment tool.65
Test–retest reliability
A subset of four subjects returned for two follow-up resting-state
fMRI scans. To avoid bias from acute effects of treatment, these
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scans were completed at least 3 months after completion of study
treatments. Parameters for each imaging sequence were identical to
the initial and final study visits. The follow-up session included one
structural T1 MPRAGE sequence and six 5.5-min BOLD runs
following the same protocol as the pre-treatment and post-
treatment imaging sessions. After the first three BOLD runs, each
subject was removed from the scanner and asked to take a 5-min
break. The subject was then placed back into the scanner for the
final three BOLD runs. Connectivity results from these sessions
were used for analysis of test–retest reliability.
Statistical analysis
Clinical measures. The primary analysis of the primary
outcome measure was mean percentage change in MADRS, which
was compared between the active and sham groups. The original
plan was to perform unpaired two-tailed t-tests at the interim and
final analyses. Because the study stopped before the planned in-
terim analyses, no formal test of statistical significance was per-
formed for treatment-induced changes. Instead, effect sizes are
reported for the purposes of planning future trials. Equality of
variances was assessed via F-tests.
Secondary analyses of the primary outcome included
mean percentage change in individual MADRS sub-
scales. Secondary outcomes included changes in NIH Toolbox
cognitive composite scores; NIH Toolbox emotional composite
scores; temperament and character inventory scales; and HIT-6 and
headache Likert scores.
Imaging analyses. A whole–brain ‘‘winner-take-all’’ par-
cellated map was generated by assigning each voxel to the network
with which it demonstrated the highest likelihood of membership.
The networks identified by this parcellated map were used as re-
gions of interest (ROIs) for seed-based connectivity analysis.
BOLD time courses were analyzed for seed-based functional
connectivity by determining covariance matrices between five a
priori specified regions of interest (ROIs). ROIs included the in-
dividualized winner-take-all maps of DAN and DMN; sgACC as
defined by the meta-analysis in Fox and colleagues29; and 24-mm
diameter spherical ROIs at the left and right-sided stimulation sites
(Fig. 1A). Effect sizes were calculated to compare treatment-
induced changes in connectivity between DAN, DMN, and sgACC
in active and sham groups.
To examine connectivity-based predictors of response, the con-
nectivity of both stimulation sites with sgACC was compared with
antidepressant response. A least squares regression model was con-
structed using baseline target-sgACC connectivity and baseline
MADRS as predictors of post-treatment MADRS. Because antide-
pressant response could not be assumed to be normally distributed in
this small sample, all data were rank-transformed, which is consis-
tent with prior methods described in Weigand and colleagues.31
FIG. 1. A priori regions of interest used for functional connectivity analysis depicted on a group-mean surface projection. Dorsal attention
and default mode networks were identified using individualized winner-take-all maps for each subject. Left and right stimulation sites were
identified using the individualized difference between dorsal attention and default mode network membership likelihoods. Subgenual
anterior cingulate cortex, which was defined based on an a priori group seed, generally overlapped with the default mode network parcel.
Color image is available online.
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Imaging test–retest reliability. Test–retest reliability of the
targeting method was assessed for the four subjects who received a
pair of follow-up scan sessions several months after treatment. The
target stimulation coordinates were computed separately for each
session. Euclidean distance between this pair of coordinates was
calculated in order to confirm the intrinsic test–retest reliability of
the targeting method.
Test–retest reliability was also assessed for functional connec-
tivity measures. For each ROI, seed-based connectivity was com-
puted with the five a priori ROIs used for functional connectivity
analysis. This generated 15 connectivity values for each of the four
subjects. Pearson correlations were calculated for these 60 con-
nectivity values between pre-treatment and post-treatment scans.
The resulting correlation values were used as estimates of test–
retest reliability of the a priori ROI pairs.
Reliability of individualization. To assess whether individu-
alization was reliable, FC values and target coordinates were
compared within individuals and between individuals. We hy-
pothesized that inter-individual variability would significantly ex-
ceed intra-individual variability, suggesting that the observed
variability results from genuine differences between individuals
rather than methodological limitations.
For the four subjects who received additional test–retest scans,
individualization was assessed for ROI-ROI connectivity values.
For each ROI pair, intra-individual variability was calculated as the
mean change in connectivity between the two separate scan ses-
sions across these four subjects. To estimate inter-individual vari-
ability, this calculation was modified such that each subject’s first
scan was compared with the second scan for the other three sub-
jects. Mean inter-individual variability was compared with mean
intra-individual variability using paired t-test.
To determine whether the target remained stable during the
course of treatment, optimal stimulation sites were computed
separately for the pre-treatment scan and the post-treatment scan
for all subjects in the study. The Euclidean distance between these
two coordinates was used as an estimate of intra-individual change.
To estimate inter-individual variability, this calculation was mod-
ified such that each subject’s pre-treatment scan was compared with
the post-treatment scan for all other subjects, which is representa-
tive of the variability expected by chance. To confirm whether
individualized targets were more stable than expected by chance,
inter-individual and intra-individual variability were compared for
both targets using a permutation test.
Results
Allocation and study flow
A total of 32 subjects were assessed for eligibility with a phone
screen, of which 15 subjects were consented and randomized to
the study. The flow of participants is depicted as a Consolidated
Standards of Reporting Trials (CONSORT) diagram in Figure 2.
FIG. 2. Consolidated Standards of Reporting Trials diagram depicting flow of participants through the trial. A total of 32 subjects
were screened by phone, of which 15 were randomized. After randomization, one subject withdrew prior to starting treatment, while two
others (one active, one sham) withdrew during the course of treatment but were included in intent-to-treat analysis. Color image is
available online.
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After randomization, one subject in the sham group withdrew prior
to starting treatment. Two subjects (one active, one sham) were
unable to complete the full course of treatments within the 5-week
timeframe; in both cases, the subjects missed several visits due to
headaches. One subject in the sham group opted out of the post-
treatment MRI scanning session. Baseline clinical characteristics
(Table 1) were comparable between the active and sham groups.
The initial protocol specified that interim sample size re-
estimation would be conducted after enrolling 20 subjects. The
interim analysis was completed earlier than initially planned
because the lead investigator and the senior investigator both left
the institution for unrelated reasons. Due to the subsequent lo-
gistical challenges, recruitment was discontinued after enrolling
15 subjects.
FIG. 3. Change in Montgomery-Asberg Depression Rating Scale (MADRS) with treatment. (A) Overall MADRS improvement with
treatment was greater in the active group than the sham group. Severity grades are depicted as delineated by Muller and colleagues.70
(B) Change in individual MADRS subscores in the treatment and sham groups. **Cohen’s d = 2.0, *Cohen’s d = 1.75. Color image is
available online.
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Clinical outcomes
The primary study outcome was mean percentage improvement
in MADRS over the course of the full study period (Fig. 3A).
A Shapiro-Wilk test revealed that this parameter was normally
distributed in both the active group (W = 0.91, p = 0.32) and the
sham group (W = 0.82, p = 0.11). An F-test showed no significant
difference in variances between the two groups ( p = 0.38). MADRS
improvement was greater in the active treatment group than in the
sham group (Cohen’s d = 1.43). Because the clinical trial was dis-
continued early, statistical hypothesis confirmation testing was not
conducted. Subscores of the MADRS with the largest differences in
improvement between active treatment and sham (Fig. 3B) were
lassitude (Cohen’s d = 2.0) and suicidal thoughts (Cohen’s d = 1.75).
Additional secondary clinical outcomes included changes in
NIH Toolbox cognitive/emotional composite scores, headache
scales, and temperament/character scales (Fig. 4). Each of these
outcomes showed no clear difference between active and sham. Of
note, HIT6 headache scales suggested a trend toward improvement
in the active group, but this was confounded by the fact that these
scales were not completed by two of the subjects who withdrew
prematurely due partly to headaches.
FIG. 4. Secondary clinical outcomes. There was no significant change in secondary clinical outcome variables. (A) Active treatment was
associated with a trend toward decrease in negative affect and increase in psychological well-being. (B) Change in overall cognition showed
wide variance between subjects. (C) Active treatment did not clearly affect personality measures. (D) Likert scales and HIT6 suggested a trend
in the direction of improvement in headaches; of note, HIT6 was not completed by two subjects who withdrew early due partly to headaches.
Color image is available online.
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The most common adverse effect was transient twitching and
discomfort in the facial muscles, which was reported by seven of
nine subjects in the active group and zero of five subjects in the
sham group. Worsening headaches were reported by one subject in
the active group and one in the sham group. One subject in the
active group experienced a presyncopal episode during the first
treatment, but chose to continue with the remainder of the study.
There were no seizures or events concerning for seizure auras.
Blinding integrity
Integrity of blinding was assessed based on a post-treatment
survey of suspected group assignment. The group assignment was
correctly guessed by three of the nine subjects in the active group
and one of the five subjects in the sham group. One of the nine
subjects in the active group guessed incorrectly. The remaining
nine subjects reported that their suspicion was ‘‘50-50’’ in either
direction.
Functional connectivity
Within the active group, baseline functional connectivity (FC)
and baseline MADRS were used as predictors of post-treatment
MADRS in an effort to identify predictors of treatment response
(Fig. 5). Antidepressant response was negatively correlated with
baseline FC between the right-sided stimulation site and sgACC
(Fig. 5A; Spearman rho = 0.70, p = 0.04). Patients stimulated at
sites with stronger sgACC anti-correlation had stronger antide-
pressant responses. The left-sided stimulation site showed a trend in
the same direction, but did not reach significance (Fig. 5B).
Substantial changes in connectivity were observed within and
between the a priori ROIs (Fig. 6). These differences were most
prominent for sgACC connectivity with the left stimulation site
(Cohen’s d = -1.26) and DMN (Cohen’s d = 1.55). Within-ROI
connectivity also demonstrated substantial changes within the left
stimulation target (Cohen’s d = 1.55), the right stimulation target
(Cohen’s d = 1.04), DAN (Cohen’s d = 0.81), and DMN (Cohen’s
d = 0.77). These connectivity measures showed high test–retest
reliability with some suggestion of regression to the mean
(Fig. 7A). Despite these treatment-induced changes, within-subject
connectivity changes were significantly lower than between-
subject differences ( p = 0.0007 across all measures, Fig. 7B).
Each subject’s individualized rTMS targets remained relatively
consistent over the course of treatment (Fig. 7C). The spatial
distance between pre-treatment and post-treatment targets (intra-
individual change) was generally lower than the mean distance
between targets across all subjects (inter-individual variability).
On average, the left-sided target showed intra-individual change of
5.1 mm –2.6 mm and inter-individual variability of 7.7 – 1.1 mm
( p = 0.009). The right-sided target showed within-subject change
of 9.9 mm –8.0 mm and inter-individual variability of 11.7 mm
–1.41 mm ( p = 0.095). The magnitude of inter-individual vari-
ability appeared to exceed the intrinsic test–retest reliability of
the scans; targets identified using two back-to-back scanning
sessions were centered 0.9-8.3 mm apart. Treatment-induced
changes appeared to be within the range of the intrinsic test–
retest reliability.
Discussion
Clinical findings
The results of this pilot study provide preliminary evidence for
efficacy of rTMS in treatment-resistant depression associated with
TBI. Treatment was associated with an apparent improvement in
clinician-rated depression scales despite substantial prior treatment
resistance. On average, subjects receiving active treatment had
failed more than four conventional antidepressant treatments
over a clinical course that included over 8 years of TBI symp-
toms and nearly 5 years of depressive symptoms. Secondary
outcome measures suggested a trend toward improvement in self-
report emotional measures and crystallized cognition. The treat-
ments were generally well-tolerated. Significant treatment-induced
adverse effects were limited to a single presyncopal episode in one
subject and possible transient worsening of baseline headaches in a
different subject.
While rTMS is widely accepted as an effective antidepressant
treatment and a promising neurorehabilitative treatment, this study
represents the first pilot double-blind randomized, controlled trial
of rTMS in TBI-associated depression to our knowledge. This adds
FIG. 5. Functional connectivity as a predictor of antidepressant response. (A) Connectivity between the right-sided stimulation site
and the a priori subgenual anterior cingulate cortex (sgACC) showed a significant relationship with antidepressant response ( p = 0.04)
(B) Antidepressant response was inversely related to connectivity between the left-sided stimulation site and the a priori sgACC, but
this did not reach significance. Color image is available online.
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to the growing literature supporting the use of rTMS for neuro-
psychiatric applications. Recent literature suggests that rTMS is as
effective as pharmacotherapy for depression associated with Par-
kinson’s disease7 and stroke.8 However, this carries particular
significance for TBI patients given that several trials have failed to
demonstrate efficacy of conventional antidepressant pharmaco-
therapy in this population.11,12
The most important limitation to this study is the premature ter-
mination when only 75% of the desired minimum sample size had
been recruited. While this decision was made due to external cir-
cumstances unrelated to the study, it may introduce chronological
bias due to unobserved time trends in patient selection.68 Further, the
small sample size limits the generalizability of the findings. Re-
plication is particularly important in context of recent observations
that rTMS may be associated with a strong placebo effect in military
veterans with major depression.69 The study also was limited by
the use of an imperfect sham device—while the Magstim Alpha
sham coil can produce a similar auditory sensation, it is potentially
FIG. 6. Treatment-induced changes in functional connectivity. Active treatment led to substantial connectivity changes within and
between the five a priori regions of interest (ROIs). Statistical hypothesis testing was not conducted due the early termination of the
trial, but the magnitude and direction of effects were consistent with the a priori hypotheses. On average, there was an increase in the
magnitude of default mode network (DMN)-subgenual anterior cingulate cortex (sgACC) correlation, dorsal attention network (DAN)-
sgACC anti-correlation, and DAN-DMN anti-correlation. Connectivity generally increased within sgACC, DMN, and DAN. The left-
sided stimulation site showed an increase in magnitude of anti-correlation with sgACC and DMN, but no substantial change in
correlation with DAN. The right-sided stimulation site showed an increase in magnitude of anti-correlation with DMN and sgACC as
well as correlation with DAN. Connectivity increased within and between the two stimulation sites. Color image is available online.
‰
FIG. 7. Test–retest reliability. (A) Bland-Altman analysis showed an apparent inverse relationship between test–retest mean and test–
retest difference, suggesting likely regression to the mean. In general, the magnitude of test–retest differences was greatest for region of
interest (ROI) pairs with high baseline positive or negative connectivity. Two outliers were both related to right stimulation site
connectivity in the same subject. (B) For each ROI pair, within-subject differences in ROI-ROI connectivity were significantly lower
than between-subject differences ( p < 0.0007 across all measures). (C) Reliability and consistency of individualized repetitive tran-
scranial magnetic stimulation (rTMS) targets. The calculated ‘‘optimal’’ left and right targets remained relatively consistent over the
course of treatment, with mean variability of 5.1 mm and 9.9 mm, respectively. For the left stimulation site, permutation testing showed
that these distances were significantly smaller than those expected by random inter-individual variability ( p = 0.009). For the right
stimulation site, this difference did not reach significance ( p = 0.095). The intrinsic test–retest reliability of the targeting method ranged
between 0.9 and 8.3 mm. Color image is available online.
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distinguishable from active treatment because it does not cause facial
twitches. Due to these limitations, these results should be considered
preliminary and require replication in a larger multi-site setting.
Physiological findings
While the study was not initially powered for analysis of im-
aging data, some robust relationships were observed nonetheless.
Notably, antidepressant efficacy of rTMS was related to the degree
of functional anti-correlation between the right-sided stimulation
site and sgACC. This is consistent with prior reports showing that
antidepressant efficacy of rTMS is related to anti-correlation be-
tween the stimulation site and sgACC.29,31
Evaluation of treatment-induced changes in functional connec-
tivity demonstrated several changes consistent with the pre-
registered a priori hypotheses, suggesting successful engagement of
the intended targets. Treatment-induced changes were consistent
with the predicted directionality for nearly all a priori ROI pairs,
including DAN to DMN, DMN to sgACC, both stimulation sites to
DMN, stimulation sites to sgACC, and within-network connectivity
for all five ROIs. Surprisingly, DAN connectivity with both stimu-
lation sites was the only parameter that did not change as predicted,
indicating that the observed network dynamics were not simply
driven by changes within the stimulated site and the stimulated net-
work. Given the high test–retest reliability of connectivity values
observed in the study, it appears unlikely that treatment-induced
changes were attributable to random chance. This suggests that rTMS
can potentially modulate specific brain systems in a partially pre-
dictable manner.
In addition to the small sample size, investigation of physio-
logical changes is limited by the use of combined left-sided ex-
citatory and right-sided inhibitory treatment. This approach was
chosen in order to maximize the likelihood of treatment efficacy,
given that bilateral treatment may be more effective than unilateral
treatment for primary major depression.6 However, this may af-
fect our ability to reliably interpret physiological changes due to
unpredictable interactions between the two treatments. This not
only introduces confounds when investigating the direction and
laterality of treatment effects, but also limits the development of
clear a priori hypotheses given the lack of prior literature sur-
rounding the physiological effects of bilateral treatment. Despite
this key limitation, these data provide additional support for the
notion that rTMS can modulate interactions involving DLPFC,
sgACC, and DMN, which have been heavily implicated in major
depression.37,70
The imaging findings also provide further support for the notion
that functional connectivity-based treatment targeting may have
played a role in the clinical effects observed in this study. Our
protocol specifically targeted DAN, which has been implicated in
the chronic sequelae of TBI25 and in major depression.70 This
targeting appeared to be reliable across sessions and stable with
treatment. Treatment-induced changes and baseline predictors of
antidepressant response showed effects in the stimulated networks.
Prior literature on the topic, by contrast, implicates frontoparietal
control/central executive network.30 This discordance may be ex-
plained by the fact that group-based targeting tends to approximate
the frontoparietal control network, which is the largest network in
DLPFC at the group level.42,43 The most important future direction
includes replication of these findings in a larger sample across
multiple centers.
Using the preliminary data generated by this pilot study, a larger
replication study is already underway. An upcoming follow-up
study will directly compare the effects of rTMS with functional
connectivity-based targeting, other rTMS targeting approaches,
and effects of laterality and/or other stimulation parameters.
Meanwhile, data collection is ongoing for a physiological study
investigating the immediate functional connectivity effects of tar-
geting different individualized resting-state network maps other
than DAN and/or DMN, which will hopefully reveal potential
targets for other TBI-associated neuropsychiatric syndromes. Such
analyses are also being conducted retrospectively on rsfMRI data
that incidentally targeted different RSNs in different individuals
due to lack of individualized targeting. Together, these results will
hopefully converge to conclusively clarify the role of rTMS in TBI
and the relevance of individualized resting-state network mapping
for targeting neuromodulation.
Conclusions
This pilot study represents a novel neuromodulatory approach
to management of treatment-resistant depression associated with
traumatic brain injury. Treatment was associated with improve-
ment in depressive symptoms and neurophysiological changes in
the targeted brain networks. Given the dearth of evidence-based
treatments for this patient population, these preliminary findings
suggest a clear need for larger studies to investigate different
treatment approaches. If successfully replicated, this study paves
the way for the use of neurostimulation to target a wide variety of
behavioral manifestations of traumatic brain injury.
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